Frequency Therapeutics Inc - Asset Resilience Ratio
Frequency Therapeutics Inc (KRRO) has an Asset Resilience Ratio of 42.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Frequency Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Frequency Therapeutics Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Frequency Therapeutics Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Frequency Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see KRRO market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $68.32 Million | 42.29% |
| Total Liquid Assets | $68.32 Million | 42.29% |
Asset Resilience Insights
- Very High Liquidity: Frequency Therapeutics Inc maintains exceptional liquid asset reserves at 42.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Frequency Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Frequency Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Frequency Therapeutics Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Frequency Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.14% | $70.45 Million | $226.24 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $221.66 Million | -- |
| 2022-12-31 | 25.65% | $18.91 Million | $73.74 Million | -1.90pp |
| 2021-12-31 | 27.55% | $51.07 Million | $185.36 Million | +19.85pp |
| 2019-12-31 | 7.70% | $17.20 Million | $223.22 Million | -- |
About Frequency Therapeutics Inc
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oli… Read more